

# Grant E. Barber

250 Baldwin Ave, Apt 509 San Mateo 94401  
Phone (608) 320-5586 Email: [gbarber@stanford.edu](mailto:gbarber@stanford.edu)

## EDUCATION

---

### **Stanford University Hospital, July 2022-June 2023**

- Advanced IBD Fellowship

### **Stanford University, September 2020-May 2022**

- Master's degree in Clinical Research and Epidemiology

### **Stanford University Hospital, July 2019-June 2022**

- Gastroenterology Fellowship
- Chief Fellow, 3/2021-6/2022

### **Stanford University Hospital, June 2016-June 2019**

- Internal Medicine Residency

### **Harvard Medical School, August 2012-May 2016**

- M.D. May 2016

### **University of Wisconsin—Madison, August 2008-May 2012**

- B.S. in Science with Honors in Research, Biochemistry

## ACADEMIC APPOINTMENT AND ROLES

---

Clinical Assistant Professor of Medicine, Division of Gastroenterology & Hepatology, Stanford University School of Medicine, Year: 2024-Present

In this position, I actively manage a predominantly IBD population of >400 patients. I see patients as numerous roles, including longitudinal IBD, tertiary consultant for complex IBD patients, and in the multi-disciplinary medical surgery IBD clinic. Besides clinical care, I supervise senior fellows in my IBD clinic, manage endoscopy for patients, and serve as the site lead for intestinal ultrasound at Stanford's flagship GI location in Redwood City.

Director of Inpatient Inflammatory Bowel Disease, Division of Gastroenterology & Hepatology, Stanford University School of Medicine, Year: 2024-Present

I created the inpatient IBD service at Stanford, which now includes an inpatient primary IBD service nested within the GI primary service, the IBD consult line which I direct, and the post-discharge IBD pathway. I received hospital funding to build and manage this program, which has seen significant improvement in hospital metrics (length of stay, readmission, patient satisfaction). I also conduct weekly case conferences with the GI fellows.

Clinical Competency Committee, Division of Gastroenterology & Hepatology, Stanford University School of Medicine, Year: 2024-Present

I serve on the CCC to evaluate fellows on a biannual basis for adequate progression through the GI fellowship, including reviews of their professional development plans, research progress, endoscopy numbers, and clinical evaluations.

GI Quality Council, Division of Gastroenterology & Hepatology, Stanford University School of Medicine  
Year: 2024-Present

I serve on the Stanford GI Quality council where we meet monthly to review opportunities for system improvement and quality concerns. I have routinely presented my own quality improvement projects before this committee as well.

## Mentor for Resident and Fellow Research Projects

I have mentored 10 trainees, including medical students, internal medicine residents, gastroenterology fellows, and a health policy Ph.D student in numerous research projects in inflammatory bowel diseases. All have published and/or presents their research projects with me.

## ACTIVE RESEARCH PROJECTS

---

**COMET-UC (2025- present):** Co-PI with Dr. Peter Higgins from University of Michigan. This is a multi-center (>20 sites), randomized controlled trial to evaluate the efficacy of infliximab versus upadacitinib in hospitalized patients with acute, severe ulcerative colitis. Funding decision from PCORI pending.

**Stanford SIMBA study (2018-Present):** PI. This is a prospective, single center observational study evaluating the safety of advanced immunologic therapies.

**Cost effectiveness of IBD Therapies (2022-present),** PI. I have directed numerous projects in conjunction with experts in our health policy division to model the costs and decision-making of therapeutic strategies in IBD.

**Optimizing Inpatient IBD care (2022-present),** PI. I have multiple ongoing retrospective studies evaluating the efficacy of my inpatient IBD program and post-discharge transitions-of-care services.

**De Novo IBD following solid organ transplant (2025-Present),** lead-PI. I am directing a multi-center retrospective study through the WECARE consortium to explore the epidemiology and comparative effectiveness of therapies in patients with de novo IBD following solid organ transplant. Participating sites additionally include Johns Hopkins, UCLA, and Oregon.

**Combination therapy with infliximab in IBD (2025-Present),** PI. In this retrospective study, I am evaluating the efficacy of combination thiopurines and methotrexate with infliximab in patients with IBD. This project is near completion and awaiting presentation at DDW and publication

## PUBLICATIONS

---

- Dupenloup, P.,.....**Barber, GE** (2026). Infliximab Monotherapy versus Infliximab and Azathioprine combination therapy in patients with Ulcerative Colitis: A Cost-Effectiveness Analysis. *Dig Dis Sci* (2026). Feb;22.
- Kulkarni, C...**Barber, GE**...Sinha SR (2026). A Fasting-Mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial. *Nature Medicine*. Jan 13, Epub ahead of print PMID: 41530382
- Dimopoulous-Verma, C...**Barber, GE** (2025). Gastroenterology Fistulizing and Stricturing Esophageal Crohn's Disease Requiring Esophagectomy. *ACG Case Rep J*. Feb 1;12(2):e01604.
- Dupenloup, P, ... **Barber, GE** (2025). Therapeutic Drug Monitoring in Patients with Ulcerative Colitis on Infliximab: A Cost-Effectiveness Analysis. *Dig Dis Sci*. Feb;70(2):728-739.
- Bugwadia, AK...**Barber, GE** (2024). Caring for Youn Adult Men with Inflammatory Bowel Disease: Clinician and Patient Perspectives. *Health Care Transi*. Jan 31;2:100043.
- Barber GE\***, Zhuo J\*, Okafor PN, Streett S (2024). Gastroenterology Clinic Follow-Up Reduces Gastroenterology-Specific Readmissions Among Patients With Severe Ulcerative Colitis. *Inflamm Bowel Dis*. Aug 1;30(8):1319-1325.
- Barber GE\***, Gubatan J.(2023). Editorial: treat-to-target in ulcerative colitis management-a small price to pay? *Aliment Pharmacol Ther*. Mar;57(5):569-570.
- Barber G.E.\***, Gubatan, J.\* et al (2023). Paternal Biologic Exposure in Inflammatory Bowel Disease patients and Adverse Pregnancy Outcomes and Sperm Parameters: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hep*. Aug;21(9):2222-2238.
- Barber G.E.**, Hendler S., Choe M., Keyashian K., Lechner S., Limketkai B.N., Limsui D. (202). Thiopurine Monotherapy is effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease. *Dig Dis Sci*. 2022 Apr;67(4) 1287-1294.
- Hendler S., **Barber G.E.**, Okafor P., Chang M., Limsui D., Limketkai, B.N. (2020). Cytomegalovirus Infection is associated with Worse Outcomes in Inflammatory Bowel Disease Hospitalizations Nationwide. *International Journal of Colorectal Disease*.

- Barber G.E.**, Hendler S., Okafor P., Limsui D., & Limketkai B.N. (2018). Rising Incidence of Intestinal Infections in Inflammatory Bowel Disease: A Nationwide Analysis." *Inflammatory Bowel diseases*.
- Barber G.E.**, Yajnik V., Khalili H., Giallourakis C., Garber J., Xavier R., & Ananthakrishnan A. N. (2016). Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. *The American Journal of Gastroenterology*, 111(12), 1816-1822.
- Barber G.E.**, Ganatra R.B., Bortinger J.Z., Hale A.J. (2015). Strongyloidiasis with Severe Malnourishment and Hyponatremia after Suboptimal Anthelmintic Therapy: A Case Report and Review of the Literature. *Infectious Diseases in Clinical Practice*.
- Rodrigues R., **Barber, G.E.**, & Ananthakrishnan, A. N. (2016). A Comprehensive Study of Costs Associated with Recurrent Clostridium difficile Infection. *Infection Control & Hospital Epidemiology*, 196-202.
- Wen J., **Barber G.E.**, & Ananthakrishnan A.N. (2015). Identification of Recurrent Clostridium difficile Infection Using Administrative Codes: Accuracy and Implications for Surveillance. *Infection Control & Hospital Epidemiology*, 1-6.
- Stefely J.A., Reidenbach AG, Ulbrich A, Oruganty K, Floyd BJ, Jochem A, Saunders JM, Johnson IE, Minogue CE, Wrobel RL, **Barber G. E.**, Lee D, Li S, Kannan N, Coon JJ, Bingman CA, Pagliarini DJ. (2014). Mitochondrial ADCK3 Employs an Atypical Protein Kinase-like Fold to Enable Coenzyme Q Biosynthesis. *Molecular Cell*, 86-94.

#### ORAL PRESENTATIONS

---

- Barber G.E.** (March 2025). Biosimilars: Boons and Burdens. MyIBD, Crohn's and Colitis Foundation.
- Barber G.E.** (May 2023). Cost-effectiveness analysis of therapeutic drug monitoring in ulcerative colitis patients on infliximab. *Digestive Disease Week*, Chicago, IL.
- Barber G.E.** (May 2022). Paternal Exposure to Inflammatory Bowel Disease Medications and Neonatal Outcomes. *Digestive Disease Week*, San Diego, CA.
- Barber G.E.** (April 2016). A Costly Mistake in Treating Strongyloides Infection. *Society for General Internal Medicine*, Yale University, New Haven, CT.
- Barber G.E.** (April 2012). Exploring the Role of an Atypical Kinase in Ubiquinone Biosynthesis. *American Society for Biochemistry and Molecular Biology*, San Diego, CA.

#### POSTER PRESENTATIONS

---

- Barber G.E.**, Zhou, J., Okafor, P., Streett, S.E. (May 2022). Outpatient Gastroenterology follow-up reduces GI-specific readmissions among patients hospitalized with acute severe ulcerative colitis." *Digestive Disease Week*, San Diego, CA.
- Gubatan J, **Barber G.E.**, Nielsen O, Juhl C., Maxwell C., Eisenberg M., Streett S. (May 2021). "Paternal Biologic and Thiopurine Exposure in Inflammatory Bowel Disease and Association with Adverse Pregnancy Outcomes and Semen Parameters: A Systematic Review and Meta-Analysis." *Digestive Disease Week*
- Barber G.E.**, Hendler S., Lechner S., Limsui D., & Limketkai B.N. (May, 2019). "Opportunistic Infections in Inflammatory Bowel Disease: A Nationwide Analysis." *Digestive Disease Week*, San Diego, CA.
- Barber G.E.**, Hendler S., Okafor P., Limsui D., & Limketkai B.N. (2018). A Nationwide survey of Intestinal Infections in Inflammatory Bowel Disease." *Stanford Research Symposium*, Stanford, CA.
- Hendler S., **Barber G.E.**, Chang M., Okafor P., Limketkai B.N. (2018). Longitudinal and nationwide analysis of the incidence and impact of cytomegalovirus infection on IBD hospitalizations. *Digestive Disease Week*, D.C.
- Barber G.E.**, Yajnik V, Khalili H, Giallourakis C, Garber J, Xavier R, Ananthakrishnan A.N. (May 2016). Genetic Markers Predict Primary non-response and Durable Response to anti-TNF Biologic Therapies in Crohn's Disease. *Digestive Disease Week*, San Diego, CA.
- Reidenbach A., **Barber G.E.**, et al. (April 2014). X-ray Structure of the human mitochondrial kinase ADCK3 elucidates the kinase fold of the ancient UbiB family, *American Society for Biochemistry and Molecular Biology*, San Diego, CA.
- Barber G.E.**, Zhao J.J. (2013). Characterizing the Signaling Pathway Dependency of Basal-like Breast Cancer. *Soma-Weiss Research Symposium*, Harvard Medical School, Boston MA.
- Barber G.E.**, Stefely J.A., Pagliarini D.J. (April 2012). Methods for Identifying Substrates of Atypical Mitochondrial Kinases. *American Society for Biochemistry and Molecular Biology*, San Diego, CA.

## AWARDS

---

Excellence in Teaching, Stanford Department of Medicine, 2/2026

Fellows Teaching Award, Stanford Division of Gastroenterology and Hepatology, 6/2025

## PROFESSIONAL MEMBERSHIPS

---

American College of Gastroenterology (ACG)

Crohn's and Colitis Foundation (CCF)